Tier 3 — preclinical

Sirtuin 6: linking longevity with genome and epigenome stability

Anatoly Korotkov, Andrei Seluanov, Vera Gorbunova

Trends in Cell Biology 2021 Volume 31, Issue 12, pages 994–1006

Bibliography

DOI: 10.1016/j.tcb.2021.06.009
PubMed: PMID 34281779
PubMed Central: PMC8903056
Funding: The work in the authors' laboratories is supported by grants from the US National Institutes of Health.
Competing interests: The authors declare no competing interests. Senior author Vera Gorbunova subsequently disclosed serving on the DoNotAge and Genflow Scientific Advisory Boards in Simon et al. 2022. This was not disclosed at the time of the 2021 review's publication.

Study snapshot

Design	Narrative review
Model	Review scope: mammalian SIRT6 knockout mice (multiple genetic backgrounds), SIRT6-overexpressing mice (Kanfi 2012, Roichman 2021), SIRT6 knockout monkeys and human perinatal SIRT6 mutations, human tissue expression studies, human polymorphism association studies, and mechanistic cell and biochemical work on SIRT6 in DNA repair, heterochromatin, telomere and centromere maintenance, and LINE1 silencing. Reviews synthetic activators (MDL-800, UBCS039) and natural activators (cyanidin, quercetin derivatives, licorine, fucoidan).
Sample	Not applicable (review)
Intervention	Not applicable (review). Notes small clinical studies on fucoidan supplementation in elderly Japanese adults (immune response to influenza vaccine, n reported in cited primary studies) and in advanced cancer patients.
Duration	Not applicable (review)
Endpoints	SIRT6 role in mammalian lifespan; SIRT6 role in DNA double-strand break repair (NHEJ and HR); SIRT6 role in base excision and nucleotide excision repair; SIRT6 regulation of telomeric and pericentric heterochromatin; SIRT6 silencing of LINE1 retrotransposons; SIRT6 interaction with Lamin A/C; SIRT6 role in cellular reprogramming and epigenetic rejuvenation; SIRT6 modulation by natural and synthetic activators

What the study showed, in plain terms

This is a review of what was known about the SIRT6 gene and ageing as of 2021. Its senior author, Vera Gorbunova, runs one of the labs that originally identified SIRT6 as a longevity-linked enzyme. The review pulls together evidence from mice, monkeys, human cells, and human tissue studies to argue that SIRT6 sits at a crossroads between two of the most important drivers of ageing: DNA damage accumulation and the gradual loss of the normal chromatin structure that keeps genes switched on or off in the right places.

The core case is straightforward. Mice with SIRT6 completely knocked out die within weeks and show accelerated ageing features. Mice with SIRT6 knocked out in specific tissues develop tissue-specific ageing pathologies. Monkeys and human infants with inactivating SIRT6 mutations do not survive. Conversely, mice engineered to make more SIRT6 than normal live substantially longer — median lifespan is extended by 27% in males and 15% in females in the most striking published study (Roichman 2021, cited here). Across mammalian species, higher SIRT6 activity correlates with longer maximum lifespan.

The review then walks through how SIRT6 does this at the molecular level: helping repair DNA double-strand breaks by activating PARP1 and recruiting repair factors, maintaining tightly packed heterochromatin at telomeres and centromeres, and silencing "jumping gene" retrotransposons (particularly LINE1) that otherwise reactivate with age and drive inflammation. The final section discusses how to activate SIRT6 as a possible longevity strategy — through fasting and calorie restriction (which raise SIRT6 naturally), through synthetic activators like MDL-800, and through natural compounds including cyanidin (identified as a 55-fold in vitro activator of SIRT6), quercetin derivatives, and fucoidan from brown seaweed.

Key findings

SIRT6 knockout in mice causes a severe progeroid phenotype with death within weeks on a 129/SvJ background; SIRT6 knockout in monkeys is embryonically or perinatally lethal in males; a homozygous inactivating SIRT6 D63H mutation in humans causes perinatal lethality.
SIRT6 overexpression under a CAG promoter extends median lifespan by 27% in male mice and 15% in female mice, with improvements in β-oxidation, hepatic glucose handling, adipose glycerol release, and reduced neoplasm incidence (Roichman 2021, as reviewed).
SIRT6 has three enzymatic activities relevant to ageing: histone deacetylation (H3K9, H3K18, H3K56), long-chain fatty-acyl deacylation, and mono-ADP-ribosylation of substrates including PARP1, KAP1, BAF170, and KDM2A.
SIRT6 stimulates both non-homologous end joining and homologous recombination DSB repair. SIRT6 mono-ADP-ribosylates PARP1 on K521 under oxidative stress, activating PARP1 and recruiting repair factors including MRE11, NBS1, 53BP1, BRCA1, and Rad51.
SIRT6 maintains heterochromatin at telomeres (via H3K9 and H3K56 deacetylation, TRF2 stabilisation, and WRN recruitment), at centromeres (via H3K18 deacetylation to prevent mitotic errors), and at LINE1 retrotransposon loci (via KAP1 ribosylation to promote HP1-mediated silencing).
Loss of SIRT6 leads to LINE1 retrotransposon derepression, accumulation of LINE1 cDNA in cytoplasm, activation of the cGAS-STING-IFN type I pathway, and sterile inflammation — a mechanism directly linked to age-related tissue inflammation.
SIRT6 interacts directly with Lamin A/C. LMNA acts as an endogenous activator of SIRT6 deacetylation and mono-ADP-ribosylation activity. This interaction is central to a proposed model in which the SIRT6-LMNA axis maintains heterochromatin organisation of retrotransposons and controls the rate of epigenetic drift with age.
SIRT6 activators reviewed: MDL-800 (synthetic allosteric activator, active in vivo for tumour suppression and pluripotency); UBCS039 (synthetic, promotes autophagy); the polyphenol cyanidin (55-fold in vitro activation, reviewed from Rahnasto-Rilla 2018); quercetin derivatives (activator/inhibitor duality by structure); licorine (transcriptional activator of SIRT6); and fucoidan from brown seaweed (in vitro SIRT6 activation, linked to immune and other health outcomes in cited small human trials).
Calorie restriction and fasting increase SIRT6 expression naturally; short-term calorie restriction has been shown to enhance NHEJ DSB repair in mice.

What this study can and cannot tell us

This is a narrative review, not a systematic review or meta-analysis. The authors did not use a pre-registered search strategy or a formal quality-assessment tool. Selection of cited evidence reflects the authors' expert synthesis, and the review is written from the perspective of a laboratory that has actively contributed to the SIRT6-longevity literature.

The evidence base synthesised is overwhelmingly preclinical. Mouse knockout, mouse overexpression, monkey knockout, and cell-biological and biochemical work provide strong mechanistic support. Direct human data are limited to small polymorphism association studies (all underpowered), tissue expression studies showing SIRT6 decreases with age in some cell types, and observational disease-association data. There is no human intervention data on SIRT6 activation and lifespan or healthspan outcomes.

The review identifies fucoidan and cyanidin as promising SIRT6 activators based primarily on in vitro biochemical assays. The cited small human trials of fucoidan (elderly Japanese, colorectal cancer, advanced cancer) do not measure SIRT6 activity as an endpoint — they measure disease-relevant clinical outcomes, so the causal link between fucoidan intake and SIRT6 activation in humans is not established in this literature. The 55-fold activation figure for cyanidin reflects an in vitro assay result, not in vivo activity, bioavailability, or achievable tissue concentration from dietary or supplemental intake.

Commercial disclosure relevant to Biohack Blueprint readers. This review states that the authors declare no competing interests. Senior author Vera Gorbunova subsequently disclosed serving on the DoNotAge Scientific Advisory Board in Simon et al. 2022 (published the following year). DoNotAge sells the SIRT6 Activator product Biohack Blueprint reviews, and its active ingredient is fucoidan — one of the natural SIRT6 activators specifically highlighted in this review's modulation section. The COI was not disclosed at the time of this review's publication. This does not invalidate the mechanistic synthesis, but the review's specific endorsement of fucoidan among promising SIRT6 activators warrants reader awareness in the context of the SIRT6 activator supplement literature.